Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Used BioTech Company For Sale by Owner - 600M OBO.

<< Previous

Bullboard Posts

Next >>

Comment by BioTeckon Jun 17, 2022 10:37am

228 Views

Post# 34764278

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Used BioTech Company For Sale by Owner - 600M OBO.

Wish I had more free capital but not bad for a few days work! Nice work on the phone lines Selphie, you actually earned your paycheck this week.

BioTeck wrote: You are giving Spill wayyyyyy too much credit to think he planned this or anything. I bet he is angry with the seller(s) instead of being angry with himself for not seeing this coming or his overpaid staff. The volume has been piddly. Even panic selling can't get the volume on this stock up.

Rolled the dice and bought some sub 1.00.

Redbaron2211 wrote: They will buy at these prices especially when they know the company is cashed up for 3 years. Maybe this was the plan all along. Secure cash then flush out the cheap paper into institutional hands.